Errors in Abstract, Key Points, Figures, and a Table

In the article titled “Efficacy and Safety of Bimekizumab in Moderate to Severe Hidradenitis Suppurativa: A Phase 2, Double-blind, Placebo-Controlled Randomized Clinical Trial,” published online August 18, 2021, and also in the November 2021 print issue of JAMA Dermatology,¹ a number of errors have been corrected. In the Findings section of the Key Points and Results section of the Abstract, the number of participants who completed the study has been amended to 73. In Table 1, the row labeled “DLQI” (Dermatology Life Quality Index) is now labeled “DLQI, mean (SD)”; the row showing the overall abscess and inflammatory nodule (AN) count has been relabeled “AN count, mean (SD),” and the mean (SD) in the last column has been changed to “17.7 (14.8)”; 16 values in the bimekizumab, placebo, and adalimumab columns for all categories of musculoskeletal and connective tissue disorders were in the wrong location; and footnote b, pertaining to the column headed “All participants,” has been amended from “Full analysis set” to “Full analysis set except for age, sex, BMI, and prior history of musculoskeletal and connective tissue disorders, which constitute the safety set; there were no differences in participant numbers between the safety set and full analysis sets.” In Figure 2, the labels of 3 panels have been corrected: Panel B: “HiSCR responders, NRI”; Panel C: “HiSCR₇₅ responders, NRI”; Panel D: “HiSCR₉₀ responders, NRI” (HiSCR indicates Hidradenitis Suppurativa Clinical Response, with the subscript numbers representing the percentage of symptom improvement from baseline; NRI indicates nonresponder imputation). Also in Figure 2, in the Response Rate column of the table in Panel A, the NRI for placebo was ameded to “5/20.” In Figure 3, in the Panel C table, the No./total No. (%) of patients taking bimekizumab at week 6 was corrected to read “9/39 (23).” The changes do not affect the interpretation of the data or the authors’ conclusions. This article has been corrected online.